EUVIMEDEUVIMED entdecken
Crossref

Plant-derived recombinant macromolecular PAP-IgG Fc as a novel prostate cancer vaccine candidate eliciting robust immune responses

Yangjoo Kang, Deuk-Su Kim, Hyunjoo Hwang, Yerin Kim, Young-Jin Seo, Peter Hinterdorfer, Kisung Ko

Transgenic Research · 2025

DOI: 10.1007/s11248-025-00433-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transgenic Research, 2025. Verfasst von Yangjoo Kang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Medicine of College, Chung-Ang University, Seoul, South Korea. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Immunoglobulin G, Cancer Vaccines, Immunoglobulin Fc Fragments. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 63 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostatic acid phosphatase (PAP) is a specific protein that is highly expressed in prostate cancer. In this study, we constructed two recombinant PAP fusion genes: PAP fused to the immunoglobulin G (IgG) Fc fragment (designated PAP-Fc) and PAP-Fc fused to the endoplasmic reticulum retention sequence KDEL (designated PAP-FcK). Transgenic Nicotiana tabacum plants expressing these recombinant macromolecular proteins (MPs) were generated using Agrobacterium-mediated transformation, and the presence of both genes was confirmed through genomic PCR. Western blot analysis validated the expression of PAP-Fc and PAP-FcK MPs, which were successfully purified via protein A affinity chromatography. Size-exclusion high-performance liquid chromatography revealed dimeric peaks for PAP-Fc (PAP-FcP) and PAP-FcK (PAP-FcKP). Bio-transmission electron microscopy demonstrated 'Y'-shaped protein particles resembling antibody structures. Moreover, PAP-FcP and PAP-FcKP exhibited a high association rate with human FcγR and FcRn. Vaccination of mice with both PAP-FcP and PAP-FcKP resulted in increased total IgG against PAP and enhanced activation of CD4+ T cells, comparable to mice immunized with PAP, which served as a positive control. These findings indicate that both plant-derived MPs can effectively induce adaptive immunity, positioning them as promising candidates for prostate cancer vaccines. Overall, plants expressing PAP-Fc and PAP-FcK represent a viable production system for antigenic macromolecule-based prostate cancer vaccines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsImmunoglobulin GCancer VaccinesImmunoglobulin Fc FragmentsProtein Tyrosine PhosphatasesMaleAnimalsNicotianaPlants, Genetically ModifiedMiceHumansRecombinant Fusion ProteinsAcid Phosphatase

Stichwörter der Autor:innen

Prostate acid phosphataseProstate cancerProstate specific antigenTransgenic plantVaccine

Substanzen

Immunoglobulin GCancer Vaccinesprostatic acid phosphataseImmunoglobulin Fc FragmentsProtein Tyrosine PhosphatasesRecombinant Fusion ProteinsAcid Phosphatase

Autor:innen und Institutionen

  • Department of Medicine, Medicine of College, Chung-Ang University, Seoul, South Korea.
  • Department of Life Science, Chung-Ang University, Seoul, South Korea.
  • Department of Applied Experimental Biophysics, Johannes Kepler University Linz, 4040, Linz, Austria.
  • Department of Medicine, Medicine of College, Chung-Ang University, Seoul, South Korea. ksko@cau.ac.kr.

Zitieren

APA

Kang, Y., Kim, D. S., Hwang, H., Kim, Y., Seo, Y. J., Hinterdorfer, P., & Ko, K. (2025). Plant-derived recombinant macromolecular PAP-IgG Fc as a novel prostate cancer vaccine candidate eliciting robust immune responses. Transgenic Research. https://doi.org/10.1007/s11248-025-00433-0

Vancouver

Kang Y, Kim DS, Hwang H, Kim Y, Seo YJ, Hinterdorfer P, et al. Plant-derived recombinant macromolecular PAP-IgG Fc as a novel prostate cancer vaccine candidate eliciting robust immune responses. Transgenic Research. 2025. doi:10.1007/s11248-025-00433-0

BibTeX
@article{Kang2025,
  author = {Kang, Yangjoo and Kim, Deuk-Su and Hwang, Hyunjoo and Kim, Yerin and Seo, Young-Jin and Hinterdorfer, Peter and Ko, Kisung},
  title = {Plant-derived recombinant macromolecular PAP-IgG Fc as a novel prostate cancer vaccine candidate eliciting robust immune responses},
  journal = {Transgenic Research},
  year = {2025},
  doi = {10.1007/s11248-025-00433-0}
}
Kostenlos starten →